Anil Kumar | Business Development Manager
Kactus
Anil Kumar holds a Ph.D. in Protein Engineering from NTU, Singapore, and brings over a decade of experience in biopharmaceutical R&D, with expertise in protein design and therapeutic innovation for immune-oncology and autoimmune indications.
Prior to joining KACTUS Bio, Anil served as Director of Antibody Discovery and Protein Engineering at ImmunOs Therapeutics in Switzerland, where he spearheaded the development of next-generation HLA and monoclonal antibody based therapeutics. His team successfully advanced multiple immune-oncology programs, including the company’s lead candidate IOS-1002 into Phase 1 clinical development for solid tumors.
At KACTUS Bio, Anil blends his deep scientific expertise with strategic business development, aiming towards building partnerships and delivering high-quality recombinant proteins and GMP-grade enzymes to accelerate drug discovery and development efforts.
Appearances:
Festival of Biologics Day 2 @ 16:50
Advances in HLA/MHC Molecular Design and Engineering for Immunological Research
Major Histocompatibility Complex (MHC) molecules, referred to as Human Leukocyte Antigens (HLA) in humans, constitute a highly polymorphic family of cell surface glycoproteins. These molecules present intracellularly processed peptide antigens by forming stable MHC–peptide complexes. Following assembly, the complexes are trafficked to the cell membrane, where they are recognized by antigen-specific T cell receptors (TCRs), thereby triggering downstream adaptive immune responses.Given the central role of MHC molecules in antigen presentation and TCR recognition, they have become indispensable tools for TCR-based therapeutic research. To support this growing demand, KACTUS has developed a comprehensive portfolio of high-quality recombinant MHC products, including MHC monomers, tetramers, peptide-ready MHCs, as well as custom production services for both MHCs and TCRs. Our offerings span a broad range of MHC alleles and clinically relevant targets such as NY-ESO-1, KRAS, and AFP, providing versatile solutions to advance drug discovery and immunotherapy development
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events